特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
942441

ペプチド治療薬 - 世界市場の将来展望(2019年~2027年)

Peptide Therapeutics - Global Market Outlook (2019-2027)

出版日: | 発行: Stratistics Market Research Consulting | ページ情報: 英文 201 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.84円
ペプチド治療薬 - 世界市場の将来展望(2019年~2027年)
出版日: 2020年06月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 201 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のペプチド治療薬市場は、2019年に281億5,000万米ドルを占め、予測期間中に11.4%のCAGRで成長し、2027年までに667億6,000万米ドルに達すると予測されています。癌の有病率の増加、強力な製品パイプラインポートフォリオの存在、および代謝障害の症例数の増加などが市場成長の促進要因となっています。しかし、承認プロセスに関する厳しい政府規制が、市場成長を妨げています。

当レポートでは、世界のペプチド治療薬市場について調査分析し、市場概要、市場動向、市場区分、地域別の市場分析、競合情勢、主要企業などについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 イントロダクション

第3章 市場動向分析

  • 促進要因
  • 抑制要因
  • 市場機会
  • 脅威
  • 技術分析
  • アプリケーション分析
  • エンドユーザー分析
  • 新興市場
  • Covid-19の影響

第4章 ポーターのファイブフォース分析

第5章 世界のペプチド治療薬市場:タイプ別

  • イントロダクション
  • 革新的
  • ジェネリック
  • ブランド

第6章 世界のペプチド治療薬市場:メーカーの種類

  • イントロダクション
  • 外注
  • 社内
  • 受託製造機関(CMO)

第7章 世界のペプチド治療薬市場:投与経路別

  • イントロダクション
  • 非経口
  • 経口
  • 粘膜
  • 注射
  • その他の投与経路
    • 皮内

第8章 世界のペプチド治療薬市場:合成技術別

  • イントロダクション
  • 固相ペプチド合成(SPPS)
  • 液相ペプチド合成(LPPS)
  • ハイブリッドテクノロジー

第9章 世界のペプチド治療薬市場:分子の種類別

  • イントロダクション
  • バソプレシン
  • ソマトスタチン
  • ナトリウム利尿
  • 黄体形成ホルモン(LH)-放出ホルモン(LHRH)
  • インスリン
  • 免疫ペプチド
  • グルカゴンと類似体
  • カルシトニン

第10章 世界のペプチド治療薬市場:アプリケーション別

  • イントロダクション
    • ベルケード(ボルテゾミブ)
    • ゾラデックス(ゴセレリン)
    • Lupron / Enantone / Eligard(ロイプロレリン)
  • 心血管疾患
    • インテグリリン(エプチフィバチド)
    • Angiomax(ビバリルジン)
  • 代謝
    • ビエッタ(エクセナチド)
    • ビクトザ(リラグルチド)
  • 呼吸器
  • 胃腸感染症(GIT)
    • リンゼス(リナクロチド)
    • ガテックス(テデュグルタイド)
  • 疼痛
  • 皮膚科
  • 抗感染症
  • 中枢神経系
    • Copaxone(グラチラマー)
  • 腎臓
  • 感染症
    • ヴィクトレリス(ボセプレビル)
    • インシベック(テラプレビル)
  • 血液疾患
    • カルビトール(エカランチド)
    • フィラジル(イカチバント)
  • 先端巨大症
  • その他のアプリケーション
    • アレルギー/免疫
    • 骨粗鬆症

第11章 世界のペプチド治療薬市場:エンドユーザー別

  • イントロダクション
  • 製薬およびバイオテクノロジー産業
  • 病院
  • 受託調査機関
  • 学術調査機関

第12章 世界のペプチド治療薬市場: 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン
    • その他欧州
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • ニュージーランド
    • 韓国
    • その他アジア太平洋地域
  • 南米
    • アルゼンチン
    • ブラジル
    • チリ
    • その他南米
  • 中東・アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • カタール
    • 南アフリカ
    • その他中東・アフリカ

第13章 主要動向

  • 契約、パートナーシップ、コラボレーション、合弁事業
  • M&A
  • 新製品の発売
  • 拡張
  • その他の主な戦略

第14章 企業プロファイル

  • Teva Pharmaceutical
  • Bachem Holding AG
  • Sanofi
  • Pfizer Inc.
  • Amgen Inc.
  • Novartis AG
  • Lonza Inc.
  • GlaxoSmithKline (GSK)
  • Eli Lilly and Company
  • Bristol-Myers Squibb(BMS)
  • Merck & Co.
  • AstraZeneca PLC
  • Novo Nordisk A/S
  • Ipsen
  • 武田薬品工業
図表

List of Tables

  • Table 1 Global Peptide Therapeutics Market Outlook, By Region (2018-2027) ($MN)
  • Table 2 Global Peptide Therapeutics Market Outlook, By Type (2018-2027) ($MN)
  • Table 3 Global Peptide Therapeutics Market Outlook, By Innovative (2018-2027) ($MN)
  • Table 4 Global Peptide Therapeutics Market Outlook, By Generic (2018-2027) ($MN)
  • Table 5 Global Peptide Therapeutics Market Outlook, By Branded (2018-2027) ($MN)
  • Table 6 Global Peptide Therapeutics Market Outlook, By Type of Manufacturers (2018-2027) ($MN)
  • Table 7 Global Peptide Therapeutics Market Outlook, By Outsourced (2018-2027) ($MN)
  • Table 8 Global Peptide Therapeutics Market Outlook, By In-house (2018-2027) ($MN)
  • Table 9 Global Peptide Therapeutics Market Outlook, By Contract Manufacturing Organizations (CMOs) (2018-2027) ($MN)
  • Table 10 Global Peptide Therapeutics Market Outlook, By Route of Administration (2018-2027) ($MN)
  • Table 11 Global Peptide Therapeutics Market Outlook, By Pulmonary (2018-2027) ($MN)
  • Table 12 Global Peptide Therapeutics Market Outlook, By Parenteral (2018-2027) ($MN)
  • Table 13 Global Peptide Therapeutics Market Outlook, By Oral (2018-2027) ($MN)
  • Table 14 Global Peptide Therapeutics Market Outlook, By Mucosal (2018-2027) ($MN)
  • Table 15 Global Peptide Therapeutics Market Outlook, By Injection (2018-2027) ($MN)
  • Table 16 Global Peptide Therapeutics Market Outlook, By Other Route of Administrations (2018-2027) ($MN)
  • Table 17 Global Peptide Therapeutics Market Outlook, By Nasal (2018-2027) ($MN)
  • Table 18 Global Peptide Therapeutics Market Outlook, By Intradermal (2018-2027) ($MN)
  • Table 19 Global Peptide Therapeutics Market Outlook, By Synthesis Technology (2018-2027) ($MN)
  • Table 20 Global Peptide Therapeutics Market Outlook, By Solid Phase Peptide Synthesis (SPPS) (2018-2027) ($MN)
  • Table 21 Global Peptide Therapeutics Market Outlook, By Liquid Phase Peptide Synthesis (LPPS) (2018-2027) ($MN)
  • Table 22 Global Peptide Therapeutics Market Outlook, By Hybrid Technology (2018-2027) ($MN)
  • Table 23 Global Peptide Therapeutics Market Outlook, By Type of Molecule (2018-2027) ($MN)
  • Table 24 Global Peptide Therapeutics Market Outlook, By Vasopressin (2018-2027) ($MN)
  • Table 25 Global Peptide Therapeutics Market Outlook, By Somatostatin (2018-2027) ($MN)
  • Table 26 Global Peptide Therapeutics Market Outlook, By Natriuretic (2018-2027) ($MN)
  • Table 27 Global Peptide Therapeutics Market Outlook, By Luteinizing Hormone (LH)-Releasing Hormone (LHRH) (2018-2027) ($MN)
  • Table 28 Global Peptide Therapeutics Market Outlook, By Insulins (2018-2027) ($MN)
  • Table 29 Global Peptide Therapeutics Market Outlook, By Immunopeptide (2018-2027) ($MN)
  • Table 30 Global Peptide Therapeutics Market Outlook, By Glucagon and Analogs (2018-2027) ($MN)
  • Table 31 Global Peptide Therapeutics Market Outlook, By Calcitonin (2018-2027) ($MN)
  • Table 32 Global Peptide Therapeutics Market Outlook, By Application (2018-2027) ($MN)
  • Table 33 Global Peptide Therapeutics Market Outlook, By Cancer (2018-2027) ($MN)
  • Table 34 Global Peptide Therapeutics Market Outlook, By Velcade (Bortezomib) (2018-2027) ($MN)
  • Table 35 Global Peptide Therapeutics Market Outlook, By Zoladex (Goserelin) (2018-2027) ($MN)
  • Table 36 Global Peptide Therapeutics Market Outlook, By Lupron/ Enantone/ Eligard (Leuprorelin) (2018-2027) ($MN)
  • Table 37 Global Peptide Therapeutics Market Outlook, By Cardiovascular Disorder (2018-2027) ($MN)
  • Table 38 Global Peptide Therapeutics Market Outlook, By Integrilin (Eptifibatide) (2018-2027) ($MN)
  • Table 39 Global Peptide Therapeutics Market Outlook, By Angiomax (Bivalirudin) (2018-2027) ($MN)
  • Table 40 Global Peptide Therapeutics Market Outlook, By Metabolic (2018-2027) ($MN)
  • Table 41 Global Peptide Therapeutics Market Outlook, By Byetta (Exenatide) (2018-2027) ($MN)
  • Table 42 Global Peptide Therapeutics Market Outlook, By Victoza (Liraglutide) (2018-2027) ($MN)
  • Table 43 Global Peptide Therapeutics Market Outlook, By Respiratory (2018-2027) ($MN)
  • Table 44 Global Peptide Therapeutics Market Outlook, By Gastro-Intestinal Infection (GIT) (2018-2027) ($MN)
  • Table 45 Global Peptide Therapeutics Market Outlook, By Linzess (Linaclotide) (2018-2027) ($MN)
  • Table 46 Global Peptide Therapeutics Market Outlook, By Gattex (Teduglutide) (2018-2027) ($MN)
  • Table 47 Global Peptide Therapeutics Market Outlook, By Pain (2018-2027) ($MN)
  • Table 48 Global Peptide Therapeutics Market Outlook, By Dermatology (2018-2027) ($MN)
  • Table 49 Global Peptide Therapeutics Market Outlook, By Anti-infection (2018-2027) ($MN)
  • Table 50 Global Peptide Therapeutics Market Outlook, By Central Nervous System (2018-2027) ($MN)
  • Table 51 Global Peptide Therapeutics Market Outlook, By Copaxone (Glatiramer) (2018-2027) ($MN)
  • Table 52 Global Peptide Therapeutics Market Outlook, By Renal (2018-2027) ($MN)
  • Table 53 Global Peptide Therapeutics Market Outlook, By Infection (2018-2027) ($MN)
  • Table 54 Global Peptide Therapeutics Market Outlook, By Victrelis (Boceprevir) (2018-2027) ($MN)
  • Table 55 Global Peptide Therapeutics Market Outlook, By Incivek (Telaprevir) (2018-2027) ($MN)
  • Table 56 Global Peptide Therapeutics Market Outlook, By Hematological Disorders (2018-2027) ($MN)
  • Table 57 Global Peptide Therapeutics Market Outlook, By Kalbitor (Ecallantide) (2018-2027) ($MN)
  • Table 58 Global Peptide Therapeutics Market Outlook, By Firazyr (Icatibant) (2018-2027) ($MN)
  • Table 59 Global Peptide Therapeutics Market Outlook, By Acromegaly (2018-2027) ($MN)
  • Table 60 Global Peptide Therapeutics Market Outlook, By Other Applications (2018-2027) ($MN)
  • Table 61 Global Peptide Therapeutics Market Outlook, By Allergy/Immunological (2018-2027) ($MN)
  • Table 62 Global Peptide Therapeutics Market Outlook, By Osteoporosis (2018-2027) ($MN)
  • Table 63 Global Peptide Therapeutics Market Outlook, By End User (2018-2027) ($MN)
  • Table 64 Global Peptide Therapeutics Market Outlook, By Pharmaceutical and Biotechnology Industries (2018-2027) ($MN)
  • Table 65 Global Peptide Therapeutics Market Outlook, By Hospitals (2018-2027) ($MN)
  • Table 66 Global Peptide Therapeutics Market Outlook, By Contract Research Organization (2018-2027) ($MN)
  • Table 67 Global Peptide Therapeutics Market Outlook, By Academic and Research Institutes (2018-2027) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

目次

According to Stratistics MRC, the Global Peptide Therapeutics Market is accounted for $28.15 billion in 2019 and is expected to reach $66.76 billion by 2027 growing at a CAGR of 11.4% during the forecast period. Increasing prevalence of cancer, presence of strong product pipeline portfolio and an increasing number of cases of the metabolic disorder is driving the market growth. However, stringent government regulation for the approval process is hampering the growth of the market.

Peptides represent one of a kind class of pharmaceutical compounds; it is recognized for being adequate and specific. Demand for peptides in clinical therapeutics is increasing as peptides have low production complexity as compared with that of protein-based biopharmaceuticals, which thereby reduces overall production cost.

Based on the type, the innovative segment is going to have high growth during the forecast period owing to the increasing investments by huge pharmaceuticals in R&D for the development of novel medicines and high prescription rate. By geography, Asia Pacific is going to have high growth during the forecast period owing to the vast patient pool, increasing healthcare expenditure and demand for newer advanced therapies.

Some of the key players profiled in the Peptide Therapeutics Market include Teva Pharmaceutical, Bachem Holding AG, Sanofi, Pfizer Inc., Amgen Inc., Novartis AG, Lonza Inc., GlaxoSmithKline (GSK), Eli Lilly and Company, Bristol-Myers Squibb(BMS), Merck & Co., AstraZeneca PLC, Novo Nordisk A/S, Ipsen, and Takeda Pharmaceutical Company Limited.

Types Covered:

  • Innovative
  • Generic
  • Branded

Type of Manufacturers Covered:

  • Outsourced
  • In-house
  • Contract Manufacturing Organizations (CMOs)

Route of Administrations Covered:

  • Pulmonary
  • Parenteral
  • Oral
  • Mucosal
  • Injection
  • Other Route of Administrations

Synthesis Technologies Covered:

  • Solid Phase Peptide Synthesis (SPPS)
  • Liquid Phase Peptide Synthesis (LPPS)
  • Hybrid Technology

Type of Molecules Covered:

  • Vasopressin
  • Somatostatin
  • Natriuretic
  • Luteinizing Hormone (LH)-Releasing Hormone (LHRH)
  • Insulins
  • Immunopeptide
  • Glucagon and Analogs
  • Calcitonin

Applications Covered:

  • Cancer
  • Cardiovascular Disorder
  • Metabolic
  • Respiratory
  • Gastro-Intestinal Infection (GIT)
  • Pain
  • Dermatology
  • Anti-infection
  • Central Nervous System
  • Renal
  • Infection
  • Hematological Disorders
  • Acromegaly
  • Other Applications

End Users Covered:

  • Pharmaceutical and Biotechnology Industries
  • Hospitals
  • Contract Research Organization
  • Academic and Research Institutes

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2018, 2019, 2020, 2024 and 2027
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Peptide Therapeutics Market, By Type

  • 5.1 Introduction
  • 5.2 Innovative
  • 5.3 Generic
  • 5.4 Branded

6 Global Peptide Therapeutics Market, By Type of Manufacturers

  • 6.1 Introduction
  • 6.2 Outsourced
  • 6.3 In-house
  • 6.4 Contract Manufacturing Organizations (CMOs)

7 Global Peptide Therapeutics Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Pulmonary
  • 7.3 Parenteral
  • 7.4 Oral
  • 7.5 Mucosal
  • 7.6 Injection
  • 7.7 Other Route of Administrations
    • 7.7.1 Nasal
    • 7.7.2 Intradermal

8 Global Peptide Therapeutics Market, By Synthesis Technology

  • 8.1 Introduction
  • 8.2 Solid Phase Peptide Synthesis (SPPS)
  • 8.3 Liquid Phase Peptide Synthesis (LPPS)
  • 8.4 Hybrid Technology

9 Global Peptide Therapeutics Market, By Type of Molecule

  • 9.1 Introduction
  • 9.2 Vasopressin
  • 9.3 Somatostatin
  • 9.4 Natriuretic
  • 9.5 Luteinizing Hormone (LH)-Releasing Hormone (LHRH)
  • 9.6 Insulins
  • 9.7 Immunopeptide
  • 9.8 Glucagon and Analogs
  • 9.9 Calcitonin

10 Global Peptide Therapeutics Market, By Application

  • 10.1 Introduction
  • 10.2 Cancer
    • 10.2.1 Velcade (Bortezomib)
    • 10.2.2 Zoladex (Goserelin)
    • 10.2.3 Lupron/ Enantone/ Eligard (Leuprorelin)
  • 10.3 Cardiovascular Disorder
    • 10.3.1 Integrilin (Eptifibatide)
    • 10.3.2 Angiomax (Bivalirudin)
  • 10.4 Metabolic
    • 10.4.1 Byetta (Exenatide)
    • 10.4.2 Victoza (Liraglutide)
  • 10.5 Respiratory
  • 10.6 Gastro-Intestinal Infection (GIT)
    • 10.6.1 Linzess (Linaclotide)
    • 10.6.2 Gattex (Teduglutide)
  • 10.7 Pain
  • 10.8 Dermatology
  • 10.9 Anti-infection
  • 10.10 Central Nervous System
    • 10.10.1 Copaxone (Glatiramer)
  • 10.11 Renal
  • 10.12 Infection
    • 10.12.1 Victrelis (Boceprevir)
    • 10.12.2 Incivek (Telaprevir)
  • 10.13 Hematological Disorders
    • 10.13.1 Kalbitor (Ecallantide)
    • 10.13.2 Firazyr (Icatibant)
  • 10.14 Acromegaly
  • 10.15 Other Applications
    • 10.15.1 Allergy/Immunological
    • 10.15.2 Osteoporosis

11 Global Peptide Therapeutics Market, By End User

  • 11.1 Introduction
  • 11.2 Pharmaceutical and Biotechnology Industries
  • 11.3 Hospitals
  • 11.4 Contract Research Organization
  • 11.5 Academic and Research Institutes

12 Global Peptide Therapeutics Market, By Geography

  • 12.1 Introduction
  • 12.2 North America
    • 12.2.1 US
    • 12.2.2 Canada
    • 12.2.3 Mexico
  • 12.3 Europe
    • 12.3.1 Germany
    • 12.3.2 UK
    • 12.3.3 Italy
    • 12.3.4 France
    • 12.3.5 Spain
    • 12.3.6 Rest of Europe
  • 12.4 Asia Pacific
    • 12.4.1 Japan
    • 12.4.2 China
    • 12.4.3 India
    • 12.4.4 Australia
    • 12.4.5 New Zealand
    • 12.4.6 South Korea
    • 12.4.7 Rest of Asia Pacific
  • 12.5 South America
    • 12.5.1 Argentina
    • 12.5.2 Brazil
    • 12.5.3 Chile
    • 12.5.4 Rest of South America
  • 12.6 Middle East & Africa
    • 12.6.1 Saudi Arabia
    • 12.6.2 UAE
    • 12.6.3 Qatar
    • 12.6.4 South Africa
    • 12.6.5 Rest of Middle East & Africa

13 Key Developments

  • 13.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 13.2 Acquisitions & Mergers
  • 13.3 New Product Launch
  • 13.4 Expansions
  • 13.5 Other Key Strategies

14 Company Profiling

  • 14.1 Teva Pharmaceutical
  • 14.2 Bachem Holding AG
  • 14.3 Sanofi
  • 14.4 Pfizer Inc.
  • 14.5 Amgen Inc.
  • 14.6 Novartis AG
  • 14.7 Lonza Inc.
  • 14.8 GlaxoSmithKline (GSK)
  • 14.9 Eli Lilly and Company
  • 14.10 Bristol-Myers Squibb(BMS)
  • 14.11 Merck & Co.
  • 14.12 AstraZeneca PLC
  • 14.13 Novo Nordisk A/S
  • 14.14 Ipsen
  • 14.15 Takeda Pharmaceutical Company Limited
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.